If you are interested in showcasing your company’s services to senior clinical development executives from Chinese and US BioPharmas, please contact: email@example.com.
PPC was established in 1997 and is a subsidiary of Novotech Health Holdings ("Novotech"). Novotech is a full-service clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech Health Holdings is positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. As of August 31, 2021, NHH had a total of 2,075 FTEs working across our offices in 14 geographies in Asia-Pacific and the United States.
Redbud Medicine, established by clinical experts from the multi-national pharmaceutical companies and FDA senior reviewer, and is rooted in both China and US, which are two most important new drug R&D markets, and is a global clinical research partner of innovative biotech and biopharma companies. Redbud could deliver a regulatory strategy to medical, clinical operations to data management and biostatistics expertise etc. Redbud has a rich KOL resources and strong site networks. Redbud already built up an integrated clinical operation team and data management system and provides the rapid one-stop solutions from regulatory affairs and clinical operation of global clinical study, and the implementation of medical strategy, ensuring to accelerate the entry of Chinese innovative drugs into the world.
Jsure Health Technology
Shanghai Jsure Health Technology Co., Ltd. was established in 2008. Jsure Health is a provider of digital solutions for patients while adhering to a "patient-centered" philosophy. Jsureʼs business scope covers more than 40
different types of diseases. Additionally, Jsure Health has developed close relationships with 200+ sites and 5,000+ physicians. So far, Jsure Health has brought hope to 80,000+ patients, while over 50 new drugs have had accelerated approvals to be listed with Jsure Healthʼs efforts.
Linking the patients to hope and building new models for digital clinical research. Jsure is continuously promoting the development of healthcare.
The PPD clinical research business of Thermo Fisher Scientific is a leading global contract research organization, providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With more than 28,000 professionals worldwide, PPD has conducted clinical trials in more than 100 countries to help customers deliver life-changing therapies to improve health. We apply innovative technologies, therapeutic expertise and a firm commitment to quality to bend the cost and time curve of drug development and optimize value. For more information, visit thermofisher.com/ppd.
dMed-Clinipace is a global, full-service contract research organization (CRO) with the largest Asia-Pacific presence. Our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment, with an emphasis on personalized services and solutions, regulatory expertise, and therapeutic leadership. Our mission is to improve the way clinical research is performed in major therapeutic areas. We strive to impact the future of drug development and health care by combining the most advanced technology with the highest international clinical standards.
ICON is the world’s leading clinical research organization, powered by healthcare intelligence. From molecule to medicine, we advance clinical
research providing outsourced development and commercialization services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 39,300 employees in 138 locations in 53 countries as 2022.
For further information about ICON, visit: www.iconplc.com.
As an imaging CRO, Median Technologies has unmatched clinical, technological, and operational expertise in oncology trials. With our offices based in the US, Europe and China, we operate globally to deliver best-in-class end-to-end imaging services for your Phase I to III oncology trials. Our technology delivers high-quality image data for faster GO/NO GO decisions, with a high level of automation to reduce variability and increase accuracy and reproducibility.
Median excel in all areas of managing oncologic images in clinical trials. We are currently working with 2,400+ investigator sites throughout the world and with more than 50 biopharma sponsors. We have a unique knowledge of the various imaging criteria used in clinical trials covering all solid tumor cancer indications. We have successfully supported more than 10 new drug application approvals by China NMPA, US FDA, EMA and Japan PMDA.
Sanofi is a leading global biopharmaceutical company focused on human health. In 1982, Sanofi opened an office in China as one of the first multinational corporations to support China’s opening up and reform. Sanofi China has a diversified business that ranges from pharmaceuticals and human vaccines to consumer healthcare. We have 12 offices, 3 production sites, 4 R&D sites and 1 digital innovation hub in China. Sanofi is committed to introducing innovative medicines and vaccines faster in China, and leading digital innovations to serve the broadest base of the Chinese people.